Course Experts: Lara Abousamra, PharmD, BCPS, BCOP and Victoria Grant, PharmD, BCIDP

Course Description: This course outlines specific recommendations regarding vaccine selection and timing in patients receiving cellular therapies, including strategies to ensure successful revaccination.

[DFCI_KEYWORDS] Chronic Lymphocytic Leukemia (CLL), Bruton’s Tyrosine Kinase (BTK) Inhibitors, Pathophysiology, Prognostic Markers, Genetic Markers, Cytogenetics, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib, Lymphocytes, Lymphadenopathy, Venetoclax, Obinutuzumab, Rituximab, Fludarabine, Bendamustine, Antiplatelet, Anticoagulation, Leukocytosis